Search

Your search keyword '"A, Shotan"' showing total 128 results
Start Over Author "A, Shotan" Publisher elsevier bv
128 results on '"A, Shotan"'

1. Perinatal outcomes after in-utero exposure to beta-blockers in women with heart disease: Data from the ESC EORP registry of pregnancy and cardiac disease (ROPAC)

Author

Ramlakhan, Karishma P., primary, Roos-Hesselink, Jolien W., additional, Basso, Thomas, additional, Greenslade, Jaimi, additional, Flint, Robert B., additional, Krieger, Eric V., additional, Shotan, Avraham, additional, Budts, Werner, additional, De Backer, Julie, additional, Hall, Roger, additional, Johnson, Mark R., additional, and Parsonage, William A., additional

Published
2024
Full Text
View/download PDF

4. PO-02-086 A NOVEL ANTIBIOTIC DELIVERY APPROACH FOR SALVAGE OF CARDIOVASCULAR-IMPLANTABLE ELECTRONIC DEVICES WITH LOCALIZED INFECTION

Author

Chorin, Ehud, primary, Topaz, Moris, additional, Schwartz, Lorin A., additional, Hochstadt, Aviram, additional, Shotan, Avraham, additional, Ashkenazi, Itamar, additional, Kazatsker, Mark, additional, Carmel, Narin, additional, Topaz, Guy, additional, Oron, Yoram, additional, margolis, gilad, additional, Nof, Eyal, additional, Beinart, Roy, additional, Glikson, Michael, additional, Mazo, Anna, additional, Milman, Anat, additional, Dekel, Michal, additional, Banai, Shmuel, additional, Rosso, Raphael, additional, and Viskin, Sami, additional

Published
2023
Full Text
View/download PDF

5. Regional Antibiotic Delivery for Implanted Cardiovascular Electronic Device Infections

Author

Topaz, Moris, primary, Chorin, Ehud, additional, Schwartz, Arie Lorin, additional, Hochstadt, Aviram, additional, Shotan, Avraham, additional, Ashkenazi, Itamar, additional, Kazatsker, Mark, additional, Carmel, Narin-Nard, additional, Topaz, Guy, additional, Oron, Yoram, additional, Margolis, Gilad, additional, Nof, Eyal, additional, Beinart, Roy, additional, Glikson, Michael, additional, Mazo, Anna, additional, Milman, Anat, additional, Dekel, Michal, additional, Banai, Shmuel, additional, Rosso, Raphael, additional, and Viskin, Sami, additional

Published
2023
Full Text
View/download PDF

6. PO-02-086 A NOVEL ANTIBIOTIC DELIVERY APPROACH FOR SALVAGE OF CARDIOVASCULAR-IMPLANTABLE ELECTRONIC DEVICES WITH LOCALIZED INFECTION

Author

Ehud Chorin, Moris Topaz, Lorin A. Schwartz, Aviram Hochstadt, Avraham Shotan, Itamar Ashkenazi, Mark Kazatsker, Narin Carmel, Guy Topaz, Yoram Oron, gilad margolis, Eyal Nof, Roy Beinart, Michael Glikson, Anna Mazo, Anat Milman, Michal Dekel, Shmuel Banai, Raphael Rosso, and Sami Viskin

Subjects
Physiology (medical), Cardiology and Cardiovascular Medicine
Published
2023
Full Text
View/download PDF

8. Optimal Timing for Coronary Intervention in Patients With Transient ST-Elevation Myocardial Infarction

Author

Michael Kleiner-Shochat, Yaniv Levi, Aaron Frimerman, Naama Amsalem, Rami Abu Fanne, Jameel Mohsen, Avraham Shotan, Simcha R. Meisel, David S. Blondheim, Ariel Roguin, Ofer Kobo, and Asaf Danon

Subjects
Male, Coronary angiography, medicine.medical_specialty, Myocardial Ischemia, Improved survival, Kaplan-Meier Estimate, 030204 cardiovascular system & hematology, Coronary Angiography, Risk Assessment, Time-to-Treatment, Cohort Studies, 03 medical and health sciences, Percutaneous Coronary Intervention, 0302 clinical medicine, St elevation myocardial infarction, Intervention (counseling), Internal medicine, medicine, Humans, In patient, Medical history, Hospital Mortality, 030212 general & internal medicine, Israel, Aged, Proportional Hazards Models, Retrospective Studies, medicine.diagnostic_test, business.industry, Syndrome, Middle Aged, Survival Analysis, Treatment Outcome, Angiography, Cardiology, ST Elevation Myocardial Infarction, Population study, Female, Cardiology and Cardiovascular Medicine, business
Abstract

STEMI patients admitted urgently to the hospital but experience early complete resolution of both ischemic symptoms and ST-elevations on the electrocardiogram are diagnosed as transient STEMI (TSTEMI). Current evidence indicates that primary intervention is plausible but in certain circumstances intervention can be delayed. We sought to examine whether there is a time limit to such a delay that may affect long-term outcome. Study population included prospectively admitted TSTEMI patients whose demographics, pertinent medical history, and clinical and angiographic features were recorded. Study patients were divided by the median time interval from admission to intervention and their characteristics and long-term survival were compared. Study population comprised 260 consecutive patients (age: 57±10 years, men: 84%) diagnosed as TSTEMI who were included from January 2000 to June 2019, which represent 6% of all STEMI patients. Coronary angiography was performed in 254 patients. The median time interval from admission to angiography was 17 hours (IQR: 7.2 to 38.7 hours). Early (17 hours from admission) and late (17 hours from admission) study groups were comparable. One patient died during admission and 41 throughout the long follow-up period of 8.5 ± 5.2 years (median: 8.2 years, IQR: 3.4 to 13.1). Mortality of early-treated TSTEMI patients (11.2%) was significantly lower than of the late-treated patients (21.6%, p0.04). The Kaplan-Meier curve demonstrated a clear tendency toward improved survival in early-treated TSTEMI patients (p0.09). In conclusion, the present data suggest that TSTEMI patients should be treated, if not by primary coronary intervention, then at least within 17 hours from admission to achieve better long-term outcome.

Published
2019
Full Text
View/download PDF

9. Optimal Timing for Coronary Intervention in Patients With Transient ST-Elevation Myocardial Infarction

Author

Meisel, Simcha R, primary, Kleiner-Shochat, Michael, additional, Fanne, Rami Abu, additional, Kobo, Ofer, additional, Amsalem, Naama, additional, Frimerman, Aaron, additional, Levi, Yaniv, additional, Blondheim, David S, additional, Mohsen, Jameel, additional, Danon, Asaf, additional, Shotan, Avraham, additional, and Roguin, Ariel, additional

Published
2019
Full Text
View/download PDF

10. The impact of left ventricular ejection fraction on heart failure patients with pulmonary hypertension

Author

Zafrir, Barak, primary, Carasso, Shemy, additional, Goland, Sorel, additional, Zilberman, Liaz, additional, Klempfner, Robert, additional, Shlomo, Nir, additional, Radzishevsky, Evgeny, additional, Hasin, Tal, additional, Shotan, Avraham, additional, Vazan, Alicia, additional, Weinstein, Jean Marc, additional, Kinany, Wadi, additional, Dragu, Robert, additional, Maor, Elad, additional, Grosman-Rimon, Liza, additional, and Amir, Offer, additional

Published
2019
Full Text
View/download PDF

11. THE DIAGNOSTIC VALUE OF C-REACTIVE PROTEIN TO TROPONIN RATIO FOR THE DIFFERENTIATION OF PERIMYOCARDITIS FROM ACUTE MYOCARDIAL INFARCTION

Author

Meisel, Simcha R., primary, Muhassen, Jamil, additional, Amsalem, Naama, additional, Fanne, Rami Abu, additional, Levin, Carmel, additional, Frimerman, Aaron, additional, Asif, Aya, additional, Levi, Yaniv, additional, Blondheim, David, additional, Shotan, Avraham, additional, and Shochat, Michael Kleiner, additional

Published
2019
Full Text
View/download PDF

13. THE DIAGNOSTIC VALUE OF C-REACTIVE PROTEIN TO TROPONIN RATIO FOR THE DIFFERENTIATION OF PERIMYOCARDITIS FROM ACUTE MYOCARDIAL INFARCTION

Author

Simcha R. Meisel, Aaron Frimerman, David S. Blondheim, Aya Asif, Rami Abu Fanne, Jamil Muhassen, Naama Amsalem, Michael Shochat, Yaniv Levi, Carmel Levin, and Avraham Shotan

Subjects
medicine.medical_specialty, biology, business.industry, C-reactive protein, Inflammation, Coronary disease, medicine.disease, Troponin, Internal medicine, medicine, Cardiology, biology.protein, cardiovascular diseases, Myocardial infarction, medicine.symptom, Cardiology and Cardiovascular Medicine, business
Abstract

It is frequently difficult to differentiate between perimyocarditis and acute myocardial infarction (AMI). Diagnosis is usually established by excluding obstructive coronary disease. The primary process in perimyocarditis is inflammation, associated with high C-reactive protein (CRP) and low

Published
2019
Full Text
View/download PDF

14. INTRAVENOUS VERNAKALANT FOR THE TREATMENT OF NEW-ONSET ATRIAL FIBRILLATION IN THE EMERGENCY DEPARTMENT

Author

Jameel Mohsen, Simcha R. Meisel, Mark Kazatsker, Avraham Shotan, and Ashkar Jalal

Subjects
medicine.medical_specialty, Ventricular tissue, business.industry, medicine.medical_treatment, Atrial fibrillation, Emergency department, Atrial tissue, Antiarrhythmic agent, medicine.disease, New onset atrial fibrillation, Vernakalant, chemistry.chemical_compound, chemistry, Internal medicine, cardiovascular system, medicine, Cardiology, cardiovascular diseases, Cardiology and Cardiovascular Medicine, business, Recent onset
Abstract

Vernakalant is a novel antiarrhythmic agent with a preferential effect on atrial tissue and limited action on ventricular tissue. Intravenous vernakalant effectively converts recent onset atrial fibrillation; conversion is usually achieved quickly with a short half-life and allows early hospital

Published
2019
Full Text
View/download PDF

15. Characteristics, Management, and Outcome of Transient ST-elevation Versus Persistent ST-elevation and Non–ST-elevation Myocardial Infarction

Author

Blondheim, David S., primary, Kleiner-Shochat, Michael, additional, Asif, Aya, additional, Kazatsker, Mark, additional, Frimerman, Aaron, additional, Abu-Fanne, Rami, additional, Neiman, Elena, additional, Barel, Maguli, additional, Levy, Yaniv, additional, Amsalem, Naama, additional, Shotan, Avraham, additional, and Meisel, Simcha R., additional

Published
2018
Full Text
View/download PDF

16. Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry

Author

Canepa, Marco, primary, Fonseca, Candida, additional, Chioncel, Ovidiu, additional, Laroche, Cécile, additional, Crespo-Leiro, Maria G., additional, Coats, Andrew J.S., additional, Mebazaa, Alexandre, additional, Piepoli, Massimo F., additional, Tavazzi, Luigi, additional, Maggioni, Aldo P., additional, Crespo-Leiro, M., additional, Anker, S., additional, Mebazaa, A., additional, Coats, A., additional, Filippatos, G., additional, Ferrari, R., additional, Maggioni, A.P., additional, Piepoli, M.F., additional, Amir, O., additional, Chioncel, O., additional, Dahlström, U., additional, Delgado Jimenez, J.F., additional, Drozdz, J., additional, Erglis, A., additional, Fazlibegovic, E., additional, Fonseca, C., additional, Fruhwald, F., additional, Gatzov, P., additional, Goncalvesova, E., additional, Hassanein, M., additional, Hradec, J., additional, Kavoliuniene, A., additional, Lainscak, M., additional, Logeart, D., additional, Merkely, B., additional, Metra, M., additional, Otljanska, M., additional, Seferovic, P.M., additional, Srbinovska Kostovska, E., additional, Temizhan, A., additional, Tousoulis, D., additional, Ferreira, T., additional, Andarala, M., additional, Fiorucci, E., additional, Folkesson Lefrancq, E., additional, Glémot, M., additional, Gracia, G., additional, Konte, M., additional, Laroche, C., additional, McNeill, P.A., additional, Missiamenou, V., additional, Taylor, C., additional, Auer, J., additional, Ablasser, K., additional, Dolze, T., additional, Brandner, K., additional, Gstrein, S., additional, Poelzl, G., additional, Moertl, D., additional, Reiter, S., additional, Podczeck-Schweighofer, A., additional, Muslibegovic, A., additional, Vasilj, M., additional, Cesko, M., additional, Zelenika, D., additional, Palic, B., additional, Pravdic, D., additional, Cuk, D., additional, Vitlianova, K., additional, Katova, T., additional, Velikov, T., additional, Kurteva, T., additional, Kamenova, D., additional, Antova, M., additional, Sirakova, V., additional, Krejci, J., additional, Mikolaskova, M., additional, Spinar, J., additional, Krupicka, J., additional, Malek, F., additional, Hegarova, M., additional, Lazarova, M., additional, Monhart, Z., additional, Sobhy, M., additional, El Messiry, F., additional, El Shazly, A.H., additional, Elrakshy, Y., additional, Youssef, A., additional, Moneim, A.A., additional, Noamany, M., additional, Reda, A., additional, Abdel Dayem, T.K., additional, Farag, N., additional, Ibrahim Halawa, S., additional, Abdel Hamid, M., additional, Said, K., additional, Saleh, A., additional, Ebeid, H., additional, Hanna, R., additional, Aziz, R., additional, Louis, O., additional, Enen, M.A., additional, Ibrahim, B.S., additional, Nasr, G., additional, Elbahry, A., additional, Sobhy, H., additional, Ashmawy, M., additional, Gouda, M., additional, Aboleineen, W., additional, Bernard, Y., additional, Luporsi, P., additional, Meneveau, N., additional, Pillot, M., additional, Morel, M., additional, Seronde, M.-F., additional, Schiele, F., additional, Briand, F., additional, Delahaye, F., additional, Damy, T., additional, Eicher, J.-C., additional, de Groote, P., additional, Fertin, M., additional, Lamblin, N., additional, Isnard, R., additional, Lefol, C., additional, Thevenin, S., additional, Hagege, A., additional, Jondeau, G., additional, Le Marcis, V., additional, Ly, J.-F., additional, Coisne, D., additional, Lequeux, B., additional, Le Moal, V., additional, Mascle, S., additional, Lotton, P., additional, Behar, N., additional, Donal, E., additional, Thebault, C., additional, Ridard, C., additional, Reynaud, A., additional, Basquin, A., additional, Bauer, F., additional, Codjia, R., additional, Galinier, M., additional, Tourikis, P., additional, Stavroula, M., additional, Stefanadis, C., additional, Chrysohoou, C., additional, Kotrogiannis, I., additional, Matzaraki, V., additional, Dimitroula, T., additional, Karavidas, A., additional, Tsitsinakis, G., additional, Kapelios, C., additional, Nanas, J., additional, Kampouri, H., additional, Nana, E., additional, Kaldara, E., additional, Eugenidou, A., additional, Vardas, P., additional, Saloustros, I., additional, Patrianakos, A., additional, Tsaknakis, T., additional, Evangelou, S., additional, Nikoloulis, N., additional, Tziourganou, H., additional, Tsaroucha, A., additional, Papadopoulou, A., additional, Douras, A., additional, Polgar, L., additional, Kosztin, A., additional, Nyolczas, N., additional, Csaba Nagy, A., additional, Halmosi, R., additional, Elber, J., additional, Alony, I., additional, Shotan, A., additional, Vazan Fuhrmann, A., additional, Romano, S., additional, Marcon, S., additional, Penco, M., additional, Di Mauro, M., additional, Lemme, E., additional, Carubelli, V., additional, Rovetta, R., additional, Bulgari, M., additional, Quinzani, F., additional, Lombardi, C., additional, Bosi, S., additional, Schiavina, G., additional, Squeri, A., additional, Barbieri, A., additional, Di Tano, G., additional, Pirelli, S., additional, Fucili, A., additional, Passero, T., additional, Musio, S., additional, Di Biase, M., additional, Correale, M., additional, Salvemini, G., additional, Brognoli, S., additional, Zanelli, E., additional, Giordano, A., additional, Agostoni, P., additional, Italiano, G., additional, Salvioni, E., additional, Copelli, S., additional, Modena, M.G., additional, Reggianini, L., additional, Valenti, C., additional, Olaru, A., additional, Bandino, S., additional, Deidda, M., additional, Mercuro, G., additional, Cadeddu Dessalvi, C., additional, Marino, P.N., additional, Di Ruocco, M.V., additional, Sartori, C., additional, Piccinino, C., additional, Parrinello, G., additional, Licata, G., additional, Torres, D., additional, Giambanco, S., additional, Busalacchi, S., additional, Arrotti, S., additional, Novo, S., additional, Inciardi, R.M., additional, Pieri, P., additional, Chirco, P.R., additional, Ausilia Galifi, M., additional, Teresi, G., additional, Buccheri, D., additional, Minacapelli, A., additional, Veniani, M., additional, Frisinghelli, A., additional, Priori, S.G., additional, Cattaneo, S., additional, Opasich, C., additional, Gualco, A., additional, Pagliaro, M., additional, Mancone, M., additional, Fedele, F., additional, Cinque, A., additional, Vellini, M., additional, Scarfo, I., additional, Romeo, F., additional, Ferraiuolo, F., additional, Sergi, D., additional, Anselmi, M., additional, Melandri, F., additional, Leci, E., additional, Iori, E., additional, Bovolo, V., additional, Pidello, S., additional, Frea, S., additional, Bergerone, S., additional, Botta, M., additional, Canavosio, F.G., additional, Gaita, F., additional, Merlo, M., additional, Cinquetti, M., additional, Sinagra, G., additional, Ramani, F., additional, Fabris, E., additional, Stolfo, D., additional, Artico, J., additional, Miani, D., additional, Fresco, C., additional, Daneluzzi, C., additional, Proclemer, A., additional, Cicoira, M., additional, Zanolla, L., additional, Marchese, G., additional, Torelli, F., additional, Vassanelli, C., additional, Voronina, N., additional, Tamakauskas, V., additional, Smalinskas, V., additional, Karaliute, R., additional, Petraskiene, I., additional, Kazakauskaite, E., additional, Rumbinaite, E., additional, Vysniauskas, V., additional, Brazyte-Ramanauskiene, R., additional, Petraskiene, D., additional, Stankala, S., additional, Switala, P., additional, Juszczyk, Z., additional, Sinkiewicz, W., additional, Gilewski, W., additional, Pietrzak, J., additional, Orzel, T., additional, Kasztelowicz, P., additional, Kardaszewicz, P., additional, Lazorko-Piega, M., additional, Gabryel, J., additional, Mosakowska, K., additional, Bellwon, J., additional, Rynkiewicz, A., additional, Raczak, G., additional, Lewicka, E., additional, Dabrowska-Kugacka, A., additional, Bartkowiak, R., additional, Sosnowska-Pasiarska, B., additional, Wozakowska-Kaplon, B., additional, Krzeminski, A., additional, Zabojszcz, M., additional, Mirek-Bryniarska, E., additional, Grzegorzko, A., additional, Bury, K., additional, Nessler, J., additional, Zalewski, J., additional, Furman, A., additional, Broncel, M., additional, Poliwczak, A., additional, Bala, A., additional, Zycinski, P., additional, Rudzinska, M., additional, Jankowski, L., additional, Kasprzak, J.D., additional, Michalak, L., additional, Wojtczak Soska, K., additional, Huziuk, I., additional, Retwinski, A., additional, Flis, P., additional, Weglarz, J., additional, Bodys, A., additional, Grajek, S., additional, Kaluzna-Oleksy, M., additional, Straburzynska-Migaj, E., additional, Dankowski, R., additional, Szymanowska, K., additional, Grabia, J., additional, Szyszka, A., additional, Nowicka, A., additional, Samcik, M., additional, Wolniewicz, L., additional, Baczynska, K., additional, Komorowska, K., additional, Poprawa, I., additional, Komorowska, E., additional, Sajnaga, D., additional, Zolbach, A., additional, Dudzik-Plocica, A., additional, Abdulkarim, A.-F., additional, Lauko-Rachocka, A., additional, Kaminski, L., additional, Kostka, A., additional, Cichy, A., additional, Ruszkowski, P., additional, Splawski, M., additional, Fitas, G., additional, Szymczyk, A., additional, Serwicka, A., additional, Fiega, A., additional, Zysko, D., additional, Krysiak, W., additional, Szabowski, S., additional, Skorek, E., additional, Pruszczyk, P., additional, Bienias, P., additional, Ciurzynski, M., additional, Welnicki, M., additional, Mamcarz, A., additional, Folga, A., additional, Zielinski, T., additional, Rywik, T., additional, Leszek, P., additional, Sobieszczanska-Malek, M., additional, Piotrowska, M., additional, Kozar-Kaminska, K., additional, Komuda, K., additional, Wisniewska, J., additional, Tarnowska, A., additional, Balsam, P., additional, Marchel, M., additional, Opolski, G., additional, Kaplon-Cieslicka, A., additional, Gil, R.J., additional, Mozenska, O., additional, Byczkowska, K., additional, Gil, K., additional, Pawlak, A., additional, Michalek, A., additional, Krzesinski, P., additional, Piotrowicz, K., additional, Uzieblo-Zyczkowska, B., additional, Stanczyk, A., additional, Skrobowski, A., additional, Ponikowski, P., additional, Jankowska, E., additional, Rozentryt, P., additional, Polonski, L., additional, Gadula-Gacek, E., additional, Nowalany-Kozielska, E., additional, Kuczaj, A., additional, Kalarus, Z., additional, Szulik, M., additional, Przybylska, K., additional, Klys, J., additional, Prokop-Lewicka, G., additional, Kleinrok, A., additional, Tavares Aguiar, C., additional, Ventosa, A., additional, Pereira, S., additional, Faria, R., additional, Chin, J., additional, De Jesus, I., additional, Santos, R., additional, Silva, P., additional, Moreno, N., additional, Queirós, C., additional, Lourenço, C., additional, Pereira, A., additional, Castro, A., additional, Andrade, A., additional, Oliveira Guimaraes, T., additional, Martins, S., additional, Placido, R., additional, Lima, G., additional, Brito, D., additional, Francisco, A.R., additional, Cardiga, R., additional, Proenca, M., additional, Araujo, I., additional, Marques, F., additional, Moura, B., additional, Leite, S., additional, Campelo, M., additional, Silva-Cardoso, J., additional, Rodrigues, J., additional, Rangel, I., additional, Martins, E., additional, Sofia Correia, A., additional, Peres, M., additional, Marta, L., additional, Ferreira da Silva, G., additional, Severino, D., additional, Durao, D., additional, Leao, S., additional, Magalhaes, P., additional, Moreira, I., additional, Filipa Cordeiro, A., additional, Ferreira, C., additional, Araujo, C., additional, Ferreira, A., additional, Baptista, A., additional, Radoi, M., additional, Bicescu, G., additional, Vinereanu, D., additional, Sinescu, C.-J., additional, Macarie, C., additional, Popescu, R., additional, Daha, I., additional, Dan, G.-A., additional, Stanescu, C., additional, Dan, A., additional, Craiu, E., additional, Nechita, E., additional, Aursulesei, V., additional, Christodorescu, R., additional, Otasevic, P., additional, Simeunovic, D., additional, Ristic, A.D., additional, Celic, V., additional, Pavlovic-Kleut, M., additional, Suzic Lazic, J., additional, Stojcevski, B., additional, Pencic, B., additional, Stevanovic, A., additional, Andric, A., additional, Iric-Cupic, V., additional, Jovic, M., additional, Davidovic, G., additional, Milanov, S., additional, Mitic, V., additional, Atanaskovic, V., additional, Antic, S., additional, Pavlovic, M., additional, Stanojevic, D., additional, Stoickov, V., additional, Ilic, S., additional, Deljanin Ilic, M., additional, Petrovic, D., additional, Stojsic, S., additional, Kecojevic, S., additional, Dodic, S., additional, Cemerlic Adic, N., additional, Cankovic, M., additional, Stojiljkovic, J., additional, Mihajlovic, B., additional, Radin, A., additional, Radovanovic, S., additional, Krotin, M., additional, Klabnik, A., additional, Pernicky, M., additional, Murin, J., additional, Kovar, F., additional, Kmec, J., additional, Semjanova, H., additional, Strasek, M., additional, Savnik Iskra, M., additional, Ravnikar, T., additional, Cernic Suligoj, N., additional, Komel, J., additional, Fras, Z., additional, Jug, B., additional, Glavic, T., additional, Losic, R., additional, Bombek, M., additional, Krajnc, I., additional, Krunic, B., additional, Horvat, S., additional, Kovac, D., additional, Rajtman, D., additional, Cencic, V., additional, Letonja, M., additional, Winkler, R., additional, Valentincic, M., additional, Melihen-Bartolic, C., additional, Bartolic, A., additional, Pusnik Vrckovnik, M., additional, Kladnik, M., additional, Slemenik Pusnik, C., additional, Marolt, A., additional, Klen, J., additional, Drnovsek, B., additional, Leskovar, B., additional, Fernandez Anguita, M.J., additional, Gallego Page, J.C., additional, Salmeron Martinez, F.M., additional, Andres, J., additional, Genis, A.B., additional, Mirabet, S., additional, Mendez, A., additional, Garcia-Cosio, L., additional, Roig, E., additional, Leon, V., additional, Gonzalez-Costello, J., additional, Muntane, G., additional, Garay, A., additional, Alcade-Martinez, V., additional, Lopez Fernandez, S., additional, Rivera-Lopez, R., additional, Puga-Martinez, M., additional, Fernandez-Alvarez, M., additional, Serrano-Martinez, J.L., additional, Grille-Cancela, Z., additional, Marzoa-Rivas, R., additional, Blanco-Canosa, P., additional, Paniagua-Martin, M.J., additional, Barge-Caballero, E., additional, Laynez Cerdena, I., additional, Famara Hernandez Baldomero, I., additional, Lara Padron, A., additional, Ofelia Rosillo, S., additional, Dalmau Gonzalez-Gallarza, R., additional, Salvador Montanes, O., additional, Iniesta Manjavacas, A.M., additional, Castro Conde, A., additional, Araujo, A., additional, Soria, T., additional, Garcia-Pavia, P., additional, Gomez-Bueno, M., additional, Cobo-Marcos, M., additional, Alonso-Pulpon, L., additional, Segovia Cubero, J., additional, Sayago, I., additional, Gonzalez-Segovia, A., additional, Briceno, A., additional, Escribano Subias, P., additional, Vicente Hernandez, M., additional, Ruiz Cano, M.J., additional, Gomez Sanchez, M.A., additional, Barrios Garrido-Lestache, E., additional, Garcia Pinilla, J.M., additional, Garcia de la Villa, B., additional, Sahuquillo, A., additional, Bravo Marques, R., additional, Torres Calvo, F., additional, Perez-Martinez, M.T., additional, Gracia-Rodenas, M.R., additional, Garrido-Bravo, I.P., additional, Pastor-Perez, F., additional, Pascual-Figal, D.A., additional, Diaz Molina, B., additional, Orus, J., additional, Epelde Gonzalo, F., additional, Bertomeu, V., additional, Valero, R., additional, Martinez-Abellan, R., additional, Quiles, J., additional, Rodrigez-Ortega, J.A., additional, Mateo, I., additional, ElAmrani, A., additional, Fernandez-Vivancos, C., additional, Bierge Valero, D., additional, Almenar-Bonet, L., additional, Sanchez-Lazaro, I.J., additional, Marques-Sule, E., additional, Facila-Rubio, L., additional, Perez-Silvestre, J., additional, Garcia-Gonzalez, P., additional, Ridocci-Soriano, F., additional, Garcia-Escriva, D., additional, Pellicer-Cabo, A., additional, de la Fuente Galan, L., additional, Lopez Diaz, J., additional, Recio Platero, A., additional, Arias, J.C., additional, Blasco-Peiro, T., additional, Sanz Julve, M., additional, Sanchez-Insa, E., additional, Aured-Guallar, C., additional, Portoles-Ocampo, A., additional, Melin, M., additional, Hägglund, E., additional, Stenberg, A., additional, Lindahl, I.-M., additional, Asserlund, B., additional, Olsson, L., additional, Afzelius, M., additional, Karlström, P., additional, Tengvall, L., additional, Wiklund, P.-A., additional, Olsson, B., additional, Kalayci, S., additional, Cavusoglu, Y., additional, Gencer, E., additional, Yilmaz, M.B., additional, and Gunes, H., additional

Published
2018
Full Text
View/download PDF

18. Collateral pressure and flow in acute myocardial infarction with total coronary occlusion correlate with angiographic collateral grade and creatine kinase levels

Author

Aaron Frimerman, Simcha R. Meisel, Yoseph Rozenman, Avraham Shotan, David S. Blondheim, Michael Shochat, Jacob Shani, and Aya Asif

Subjects
medicine.medical_specialty, medicine.medical_treatment, Population, Myocardial Infarction, Collateral Circulation, Coronary Angiography, Leukocyte Count, Coronary circulation, Coronary Circulation, Internal medicine, Angioplasty, medicine, Humans, Ventricular Function, Myocardial infarction, education, Creatine Kinase, education.field_of_study, biology, business.industry, Collateral circulation, medicine.disease, Coronary arteries, medicine.anatomical_structure, Coronary Occlusion, Coronary occlusion, biology.protein, Cardiology, Creatine kinase, Cardiology and Cardiovascular Medicine, business
Abstract

The validity of angiographic collateral grade according to the Rentrop classification during acute myocardial infarction (AMI) and its relation to flow in occluded coronary arteries before angioplasty have never been evaluated.We assessed the validity of the angiographic collateral grade according to Rentrop classification in relation to collateral pressure and flow beyond occluded coronary arteries during AMI. Pressure distal to coronary artery occlusions before balloon dilatation was measured in 111 patients undergoing angioplasty for AMI. We calculated the collateral flow index (CFI) and compared it to observed Rentrop grade and measured creatine kinase sum.The values of pressure distal to coronary artery occlusions with respect to collateral grades 0 to 3 were 33 +/- 12, 37 +/- 13, 42 +/- 10, and 60 +/- 14 mm Hg (P.0001). Overall CFI was 0.35 +/- 0.13 (median 0.33), with CFI values of 0.3 +/- 0.13, 0.33 +/- 0.13, 0.39 +/- 0.1, and 0.57 +/- 0.2 for collateral grades 0 to 3, respectively (P.0001). Larger creatine kinase elevation (P.016) and higher white blood cell count (P.022) were recorded in the lowest tertile CFI compared with highest tertile CFI group; but no difference in the global, regional, or infarct-related regional left ventricular contraction was found.These observations demonstrate that the Rentrop classification is valid in AMI patients with occluded coronary arteries and that collaterals are recruited acutely. These collaterals, whose pressure-derived CFI during AMI was shown for the first time to be higher than its value reported in chronic conditions, may limit the immediate myocardial damage or the systemic inflammatory response. No impact on global or regional cardiac contraction was detected in a population where most patients were treated early.

Published
2010
Full Text
View/download PDF

19. Corrigendum to “Non-Invasive Lung Impedance-Guided Preemptive Treatment in Chronic Heart Failure Patients: A Randomized Controlled Trial (Impedance-HF Trial)”

Author

Shochat, Michael Kleiner, primary, Shotan, Avraham, additional, Blondheim, David S., additional, Kazatsker, Mark, additional, Dahan, Iris, additional, Asif, Aya, additional, Rozenman, Yoseph, additional, Kleiner, Ilia, additional, Weinstein, Jean Marc, additional, Frimerman, Aaron, additional, Vasilenko, Lubov, additional, and Meisel, Simcha R., additional

Published
2017
Full Text
View/download PDF

20. Corrigendum to ‘Ventricular tachyarrhythmia during pregnancy in women with heart disease: Data from the ROPAC, a registry from the European Society of Cardiology’ [Int. J. Cardiol. 220 (2016) 131–136]

Author

Ertekin, Ebru, primary, van Hagen, Iris M., additional, Salam, Amar M., additional, Ruys, Titia P.E., additional, Johnson, Mark R., additional, Popelova, Jana, additional, Parsonage, William A., additional, Ashour, Zeinab, additional, Shotan, Avraham, additional, Oliver, José M., additional, Veldtman, Gruschen R., additional, Hall, Roger, additional, and Roos-Hesselink, Jolien W., additional

Published
2017
Full Text
View/download PDF

21. Internal thoracic impedance monitoring: a novel method for the preclinical detection of acute heart failure

Author

Aaron Frimerman, Simcha R. Meisel, Avraham Shotan, Gideon Charach, Shmuel Meyler, Paul Rabinovich, Mark Kazatzker, Morris Mosseri, and Michael Shochat

Subjects
Adult, Male, medicine.medical_specialty, Acute coronary syndrome, Baseline level, Cardiography, Impedance, Thoracic impedance, Internal medicine, Edema, Humans, Medicine, Stage (cooking), Aged, Aged, 80 and over, Heart Failure, Lung, business.industry, General Medicine, Middle Aged, medicine.disease, Surgery, Logistic Models, medicine.anatomical_structure, Heart failure, Acute Disease, Cardiology, Feasibility Studies, Female, medicine.symptom, Cardiology and Cardiovascular Medicine, Preclinical stage, business, Algorithms
Abstract

Acute heart failure (AHF) evolves through two phases. In the first phase, there is interstitial congestion with no clinical sign of edema (preclinical phase); the second, during which lung alveoli begin to fill with fluid, manifests as clinically overt alveolar edema. Treatment of AHF at its preclinical phase can alleviate its clinical impact. Presently, there is no technique that detects the interstitial phase of AHF. We used a device based on a new method of lung bioimpedance measurement. The device measures internal thoracic impedance (ITI), which nearly equals inherent lung bioimpedance. This method can detect small changes in lung fluid that occur during the interstitial stage of AHF.The objective of this study was to assess the feasibility and efficacy of the said new method in detecting preclinical AHF.Internal thoracic impedance and pertinent clinical parameters were monitored for 72 h in 403 patients hospitalized for an acute coronary syndrome without evidence of AHF at study entry.Seventy patients developed AHF during monitoring. Internal thoracic impedance decreased in these patients by 16.4% (95% CI=-12.2% to -20.6%; P.0001) from the baseline level at 44+/-15.1 min prior to the onset of lung rales. The other 333 patients had no clinical sign of AHF, and their ITI declined only by 4.5% (95% CI=2.5% to -11.5%; P=.3) compared with the baseline level.The new method for ITI measurement is sufficiently sensitive in detecting AHF at its preclinical stage. An ITI decrease of more than 12% heralds the appearance of clinically overt AHF and, thus, allows earlier therapy.

Published
2006
Full Text
View/download PDF

22. Relation of Left Atrial Size to Function as Determined by Transesophageal Echocardiography

Author

Simcha R. Meisel, Michael Shochat, Aaron Frimerman, Avraham Shotan, David S. Blondheim, and Aya Osipov

Subjects
Male, medicine.medical_specialty, Chi-Square Distribution, business.industry, Left atrium, Reproducibility of Results, Fractional shortening, Middle Aged, medicine.disease, medicine.anatomical_structure, Left atrial, Internal medicine, Circulatory system, medicine, Cardiology, Humans, Atrial Function, Left, Female, Heart Atria, Cardiology and Cardiovascular Medicine, business, Heart atrium, Stroke, Echocardiography, Transesophageal
Abstract

One hundred thirty-nine patients who underwent transesophageal echocardiographic studies were grouped by their maximal left atrial (LA) volumes, and their stroke volumes, emptying fractions, and fractional shortening were calculated. In large atria, an inverse relation was found between further increases in LA volume and LA function, determined by emptying fractions and fractional shortening.

Published
2005
Full Text
View/download PDF

23. Corrigendum to ‘Ventricular tachyarrhythmia during pregnancy in women with heart disease: Data from the ROPAC, a registry from the European Society of Cardiology’ [Int. J. Cardiol. 220 (2016) 131–136]

Author

Gruschen R. Veldtman, Mark R. Johnson, Avraham Shotan, Iris M. van Hagen, Zeinab Ashour, William A. Parsonage, Roger Hall, Jana Popelová, Ebru Ertekin, Amar M Salam, José M. Oliver, Jolien W. Roos-Hesselink, and Titia P.E. Ruys

Subjects
Pathology, medicine.medical_specialty, Pregnancy, Heart disease, Ventricular Tachyarrhythmias, business.industry, Family medicine, medicine, Cardiology and Cardiovascular Medicine, medicine.disease, business, Bristol-Myers
Abstract

The authors regret that some dates of sponsor's involvement in the program were incorrectly reported in the initial published paper, therefore please consider the below corrected information: Since the start of EORP, the following companies have supported the programme: Abbott Vascular Int. (2011–2014), Amgen Cardiovascular (2009–2018), AstraZeneca (2014–2017), Bayer (2009–2018), Boehringer Ingelheim (2009–2016), Boston Scientific (2009–2012), The Bristol Myers Squibb and Pfizer Alliance (2011–2016), The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company (2011–2017), Gedeon Richter Plc. (2014–2017), Menarini Int. Op. (2009–2012), MSD-Merck & Co. (2011–2014), Novartis Pharma AG (2014–2017), ResMed (2014–2016), Sanofi (2009–2011), SERVIER (2009–2018). The authors would like to apologise for any inconvenience caused.

Published
2017
Full Text
View/download PDF

24. TE-TM coupled mode dynamics in a semiconductor laser subject to feedback with variably rotated polarization

Author

Zav Shotan, Noam Gross, Tal Galfsky, and Lev Khaykovich

Subjects
Physics, business.industry, Polarization (waves), Laser, Atomic and Molecular Physics, and Optics, Electronic, Optical and Magnetic Materials, law.invention, Optics, Semiconductor, law, Relative phase, Electrical and Electronic Engineering, Physical and Theoretical Chemistry, business, Lasing threshold
Abstract

We report on the experimental observation of dynamical collapses which address selectively the TM-mode of a laser subject to optical feedback with variably rotated polarization. Simultaneously, the TE-mode which remains the dominant lasing mode exhibits power bursts. We analyze the relative phase shift between the feedback fields into the TE- and TM-mode and find that the dynamical collapses, observed in a specific range of polarization rotation angles, can be attributed to large phase shift feedback conditions applied on the TM-mode.

Published
2009
Full Text
View/download PDF

25. Prevalence and prognostic significance of unrecognized systemic hypertension in patients with diabetes mellitus and healed myocardial infarction and/or stable angina pectoris

Author

Michael Motro, Valentina Boyko, Uri Goldbourt, Solomon Behar, Alexander Tenenbaum, Joseph Shemesh, Enrique Z. Fisman, Henrietta Reicher-Reiss, Ilan Auerbach, and Avraham Shotan

Subjects
Male, medicine.medical_specialty, Myocardial Infarction, Infarction, Angina Pectoris, Diabetes Complications, Diabetes mellitus, Internal medicine, Diabetes Mellitus, Prevalence, Humans, Medicine, Myocardial infarction, Aged, Proportional Hazards Models, business.industry, Proportional hazards model, Hazard ratio, Middle Aged, Prognosis, medicine.disease, Confidence interval, Cerebrovascular Disorders, Hypertension, Multivariate Analysis, Cardiology, Myocardial infarction complications, Female, Ischemic chest pain, Cardiology and Cardiovascular Medicine, business
Abstract

Few data are available regarding the prevalence and prognostic significance of the triple coexistence of undiagnosed systemic hypertension, diabetes mellitus, and coronary heart disease. This study aimed to evaluate the prevalence and prognostic significance of unrecognized hypertension in cardiac diabetic patients previously defined as "normotensives" over a 5-year follow-up period. The study sample comprised 11,515 patients aged 45 to 74 years with a previous myocardial infarction and/or anginal syndrome who were screened but not included in the Bezafibrate Infarction Prevention study. Among them, 9,033 were nondiabetics and 2,482, diabetics. The diabetics were divided into 3 groups: (1) 1,272 normotensives, (2) 152 patients without history of hypertension but with elevated blood pressure ("unrecognized hypertensives"), and (3) 1,058 hypertensives with established diagnosis. The prevalence of both diagnosed and unrecognized hypertension in diabetics pooled together increased from 49% to 69% when World Health Organization and new Joint National Committee-VI criteria were compared. Crude all-cause mortality was lower in nondiabetics than in diabetics (11.2% vs 22.0%; p

Published
1999
Full Text
View/download PDF

26. Ventricular tachyarrhythmia during pregnancy in women with heart disease: Data from the ROPAC, a registry from the European Society of Cardiology

Author

Ertekin, Ebru, primary, van Hagen, Iris M., additional, Salam, Amar M., additional, Ruys, Titia P.E., additional, Johnson, Mark R., additional, Popelova, Jana, additional, Parsonage, William A., additional, Ashour, Zeinab, additional, Shotan, Avraham, additional, Oliver, José M., additional, Veldtman, Gruschen R., additional, Hall, Roger, additional, and Roos-Hesselink, Jolien W., additional

Published
2016
Full Text
View/download PDF

27. Non-Invasive Lung IMPEDANCE-Guided Preemptive Treatment in Chronic Heart Failure Patients: A Randomized Controlled Trial (IMPEDANCE-HF Trial)

Author

Shochat, Michael Kleiner, primary, Shotan, Avraham, additional, Blondheim, David S., additional, Kazatsker, Mark, additional, Dahan, Iris, additional, Asif, Aya, additional, Rozenman, Yoseph, additional, Kleiner, Ilia, additional, Weinstein, Jean Marc, additional, Frimerman, Aaron, additional, Vasilenko, Lubov, additional, and Meisel, Simcha R., additional

Published
2016
Full Text
View/download PDF

31. Prognostic significance of cerebrovascular disease in 11,526 chronic coronary artery disease patients

Author

Avraham Shotan, Solomon Behar, Lori Mandelzweig, David Tanne, Henrietta Reicher-Reiss, Valentina Boyko, Uri Goldbourt, and Michael Jonas

Subjects
medicine.medical_specialty, Framingham Risk Score, Vascular disease, business.industry, Ischemia, medicine.disease, Comorbidity, Central nervous system disease, Coronary artery disease, Internal medicine, medicine, Cardiology, cardiovascular diseases, Cardiology and Cardiovascular Medicine, business, Complication, Stroke
Abstract

Patients with chronic CAD and a history of cerebrovascular events were compared with patients without prior cerebrovascular events to assess the effect of these events on 5-year prognosis. Despite adjustment for older age and higher comorbidity among patients who had experienced a cerebrovascular event, a history of such an event was associated with an increased risk of 1.86 for total mortality.

Published
1998
Full Text
View/download PDF

32. Effect of Beta-Blocker Therapy in Patients With Coronary Artery Disease in New York Heart Association Classes II and III

Author

Moti Haim, Henrietta Reicher-Reiss, Solomon Behar, Valentina Boyko, Uri Goldbourt, Michal Benderly, and Avraham Shotan

Subjects
medicine.medical_specialty, Bezafibrate, Beta blocker therapy, business.industry, Infarction, Cardiac mortality, medicine.disease, New york heart association, Large cohort, Coronary artery disease, Internal medicine, Cardiology, Medicine, In patient, Cardiology and Cardiovascular Medicine, business, medicine.drug
Abstract

The aim of the study was to investigate the effect of β-blocker treatment on a large cohort of patients with coronary artery disease in functional classes II and III according to the New York Heart Association (NYHA) classification. Among 11,575 patients with coronary artery disease screened for participation, but not included in the Bezafibrate Infarction Prevention (BIP) study, 3,225 (28%) were in NYHA classes II and III. In the latter group of patients we compared the prognosis of 1,109 (34%) treated with β blockers with 2,116 counterparts not receiving β-blocker therapy. After a mean follow-up of 4 years, all-cause and cardiac mortality rates were significantly lower among β-blocker users, 9% and 5%, respectively, than among β-blocker nonusers, 17% and 11%, respectively (p

Published
1998
Full Text
View/download PDF

33. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease

Author

Michael Jonas, Uri Goldbourt, Lori Mandelzweig, Avraham Shotan, Henrietta Reicher-Reiss, Valentina Boyko, and Solomon Behar

Subjects
medicine.medical_specialty, education.field_of_study, business.industry, Population, Infarction, medicine.disease, Lower risk, Coronary artery disease, Relative risk, Internal medicine, Diabetes mellitus, medicine, Cardiology, Myocardial infarction, Cardiology and Cardiovascular Medicine, education, business, Survival analysis
Abstract

The benefit of β-blocker therapy in patients after myocardial infarction is well established. The use of β blockers in the high-risk subgroup of patients with combined diabetes mellitus (DM) and coronary artery disease (CAD) remains controversial. From a database of 14,417 patients with chronic CAD who had been screened for participation in the Bezafibrate Infarction Prevention (BIP) study, 2,723 (19%) had non-insulin-dependent DM. Baseline characteristics and 3-year mortality were analyzed in patients with DM receiving (n = 911; 33%) and not receiving (n = 1,812; 67%) β blockers. Total mortality during a 3-year follow-up was 7.8% in those receiving β blockers compared with 14.0% in those who were not (a 44% reduction). A reduction in cardiac mortality of 42% between the 2 groups was also noted. Three-year survival curves showed significant differences in mortality with increasing divergence (p = 0.0001). After multiple adjustment, multivariate analysis identified β-blocker therapy as a significant independent contributor to improved survival (relative risk = 0.58; 90% confidence interval 0.46 to 0.74). Within the diabetic population, the main benefit associated with β-blocker therapy was observed in older patients, in those with a history of myocardial infarction, those with limited functional capacity, and those at lower risk. Thus, therapy with β blockers appears to be associated with improved long-term survival in the high-risk subpopulation of patients with DM and CAD.

Published
1996
Full Text
View/download PDF

34. Escalating nitrate dose overcomes early attenuation of hemodynamic effect caused by nitrate tolerance in patients with heart failure

Author

Anilkumar Mehra, Enrique Ostrzega, Avraham Shotan, Uri Elkayam, and Janet Vasquez-Johnson

Subjects
Adult, Male, Blood level, Hemodynamics, Blood Pressure, Isosorbide Dinitrate, Pulmonary Artery, Ventricular Dysfunction, Left, chemistry.chemical_compound, Nitrate, Peak effect, medicine, Humans, In patient, Pulmonary Wedge Pressure, Aged, Heart Failure, business.industry, Washout, Drug Tolerance, Middle Aged, medicine.disease, chemistry, Anesthesia, Heart failure, Female, Isosorbide dinitrate, Cardiology and Cardiovascular Medicine, business, medicine.drug
Abstract

This study was performed to examine the hypothesis that an early attenuation of nitrate effect caused by nitrate tolerance can be overcome by dose increase. We compared hemodynamic effects of constant dose (40 to 120 mg) of oral isosorbide dinitrate (ISDN) given every 6 hours for three doses followed by 12 hours of nitrate washout interval with those of escalating dose (40 mg, 80 mg, and 120 mg) in two similar groups of patients with chronic congestive heart failure. Escalating ISDN dose resulted in a progressive increase in ISDN blood level and overcame early attenuation of effect occurring with a constant dose. At peak effect of the third ISDN dose, a significantly greater reduction was seen in mean right atrial pressure (-59% +/- 27% vs -20% +/- 22%, p0.01), mean pulmonary artery pressure (-29% +/- 11% vs -11% +/- 15%, p0.01) and mean pulmonary artery wedge pressure (-39% +/- 19% vs -19% +/- 23%, p0.05) with the escalating dose. These findings demonstrate that early attenuation of hemodynamic effect caused by nitrate tolerance can be overcome by dose escalation.

Published
1995
Full Text
View/download PDF

35. One Year Follow Up after Termination Non-Invasive Lung IMPEDANCE-Guided Preemptive Treatment in Chronic Heart Failure Patients: A Randomized Controlled Trial (IMPEDANCE-HF Trial)

Author

Iris Dahan, Ilia Kleiner, David S. Blondheim, Aya Asif, Avraham Shotan, Mark Kazatsker, Jean Marc Weinstein, Simcha Meisel, and Michael Shochat

Subjects
medicine.medical_specialty, One year follow up, business.industry, Non invasive, medicine.disease, Surgery, law.invention, Randomized controlled trial, law, Heart failure, medicine, Physical therapy, Cardiology and Cardiovascular Medicine, business, Lung impedance
Published
2016
Full Text
View/download PDF

37. Risks of angiotensin-converting enzyme inhibition during pregnancy: Experimental and clinical evidence, potential mechanisms, and recommendations for use

Author

Uri Elkayam, Avraham Shotan, Josef Widerhorn, and A. K. Hurst

Subjects
medicine.medical_specialty, Captopril, Blood Pressure, Oligohydramnios, Kidney, Pulmonary hypoplasia, Fetus, Enalapril, Pregnancy, Risk Factors, Ductus arteriosus, medicine, Animals, Renal Insufficiency, Ductus Arteriosus, Patent, Fetal Death, Maternal-Fetal Exchange, Sheep, Respiratory distress, business.industry, Obstetrics, Goats, Uterus, Abnormalities, Drug-Induced, Gestational age, General Medicine, medicine.disease, Surgery, medicine.anatomical_structure, Regional Blood Flow, Gestation, Female, Vascular Resistance, Rabbits, business
Abstract

objective: To review reports on the use of angiotensin-converting enzyme inhibitors (ACE-1) during pregnancy in order to determine the incidence, nature, and potential mechanisms of fetal complications in an attempt to establish recommendations related to the use of these drugs during gestation. data sources: Relevant English-language articles identified through a Medline search and bibliographies found in recent articles. study selection: Large number of reports both on animals and on humans have consistently shown a high degree of morbidity and even mortality in fetuses or newborns exposed to ACE-1 during pregnancy. The reported complications include oligohydramnios, intrauterine growth retardation, premature labor, fetal and neonatal renal failure, bony malformations, limb contractures, persistent patent ductus arteriosus, pulmonary hypoplasia, respiratory distress syndrome, prolonged hypotension, and neonatal death. A high incidence of fetal complications was related to the use of ACE-1 at all trimesters of pregnancy. conclusion: The gestational use of ACE-1 may be associated with a high degree of fetal and newborn morbidity and even mortality. The use of these drugs should be avoided at all trimesters of pregnancy.

Published
1994
Full Text
View/download PDF

38. IMPORTANCE LUNG IMPEDANCE-GUIDED TREATMENT OF THE PATIENTS WITH ACUTE MYOCARDIAL INFARCTION FOR PREVENTING ACUTE HEART FAILURE AND REDUCING LONG-TERM MORTALITY

Author

Aya Asif, Dabid Blondheim, Elena Naiman, Avraham Shotan, Vladimir Gurovich, Ilia Shochat, Yaniv Levy, Lubov Vasilenko, Mark Kazatsker, Michael Shochat, and Simcha Meisel

Subjects
medicine.medical_specialty, business.industry, Heart failure, Internal medicine, medicine, Cardiology, Electrocardiography in myocardial infarction, Long term mortality, Myocardial infarction, medicine.disease, business, Cardiology and Cardiovascular Medicine, Lung impedance
Published
2011
Full Text
View/download PDF

39. A randomized comparison between the hemodynamic effects of hydralazine and nitroglycerin alone and in combination at rest and during isometric exercise in patients with chronic mitral regurgitation

Author

Arie Roth, Uri Elkayam, and Avraham Shotan

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Rest, Hemodynamics, Isometric exercise, Nitroglycerin, medicine.artery, Internal medicine, Heart rate, medicine, Humans, Pulmonary wedge pressure, Exercise, Aged, Analysis of Variance, business.industry, Central venous pressure, Mitral Valve Insufficiency, Middle Aged, Hydralazine, medicine.anatomical_structure, Anesthesia, Chronic Disease, Pulmonary artery, Vascular resistance, Cardiology, Drug Therapy, Combination, Female, Cardiology and Cardiovascular Medicine, business, medicine.drug
Abstract

Both arteriolar vasodilation with hydralazine and venodilation with nitroglycerin have been shown to favorably alter the hemodynamic profile in patients with chronic mitral regurgitation. Since these therapeutic modalities exert their effects by different mechanisms, this study was designed to assess hemodynamic response to both drugs given individually and in combination at rest and during isometric exercise in patients with chronic mitral regurgitation of various etiologies. When used individually, hydralazine caused larger increase in heart rate, cardiac index, stroke volume index, and systemic vascular resistance both at rest and during exercise. In contrast, nitroglycerin administration was associated with a superior effect on mean pulmonary artery pressure and V wave amplitude at rest and on mean right atrial and mean pulmonary artery wedge pressures at rest and during isometric exercise. In comparison with hydralazine alone, combination therapy enhanced the reduction in right atrial pressure (4 +/- 1 versus 0 +/- 2 mm Hg, p < 0.05), mean pulmonary arterial pressure (11 +/- 5 versus 1 +/- 3 mm Hg, p < 0.05), and the V wave amplitude (15 +/- 6 versus -5 +/- 3 mm Hg, p < 0.05) at rest and resulted in a larger reduction in exercise values of mean pulmonary artery pressure (-11 +/- 7 versus -3 +/- 5 mm Hg, p < 0.05) and mean pulmonary arterial wedge pressure (-11 +/- 5 versus -5 +/- 3 mm Hg, p < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Published
1993
Full Text
View/download PDF

44. Risk Assessment of Re-Hospitalizations for Heart Failure During 30 Days After Discharge for Acute Heart Failure

Author

Michael Shochat, Mark Kazatsker, Avraham Shotan, Aya Asif, Ilia Kleiner, David S. Blondheim, Iris Dahan, and Simcha Meisel

Subjects
medicine.medical_specialty, business.industry, Internal medicine, Heart failure, medicine, Cardiology, After discharge, Cardiology and Cardiovascular Medicine, business, Risk assessment, medicine.disease
Published
2015
Full Text
View/download PDF

47. Pregnancy associated cardiomyopathy: Clinical profile in 137 patients diagnosed in the United States

Author

Muhammad Tahir Khan, Mohammed W. Akhter, Uri Elkayam, Afshan B. Hameed, Usman Ahsan, Salman Khan, Harpreet Singh, and Avraham Shotan

Subjects
medicine.medical_specialty, Pediatrics, Pregnancy, business.industry, Cardiomyopathy, medicine.disease, Internal medicine, cardiovascular system, Cardiology, medicine, cardiovascular diseases, business, Cardiology and Cardiovascular Medicine, human activities, hormones, hormone substitutes, and hormone antagonists, circulatory and respiratory physiology
Published
2003
Full Text
View/download PDF

48. Smoking cessation and the risk of sudden cardiac death in patients with coronary heart disease

Author

Ilan Goldenberg, Solomon Behar, Michael Jonas, Henrietta Reicher-Reiss, Avraham Shotan, Valentina Boyco, and Alexander Tennenbaum

Subjects
medicine.medical_specialty, Framingham Risk Score, business.industry, medicine.medical_treatment, medicine.disease, Coronary heart disease, Sudden cardiac death, Internal medicine, medicine, Cardiology, Smoking cessation, In patient, Myocardial infarction, business, Cardiology and Cardiovascular Medicine
Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results